Highest return-on-equity Health Care companies
Health Care-sector companies ranked by trailing return on equity (ROE). Delayed fundamentals from market data, shown with their as-of date.
38 companies were left out of this ranking: 22 because equity is under half of one year's net income (ROE beyond 200%), so the ratio reflects a shrunken equity base rather than returns; 14 because shareholders' equity on the latest balance sheet is zero or negative, so a return on it is not meaningful; 2 because the latest figure is from a fiscal year older than this ranking's window.
Ranked by ROE, AVEANNA HEALTHCARE HOLDINGS INC (AVAH) leads the covered catalog at +115.7%.
| # | Company | Sector | ROE | Net margin | Market cap |
|---|---|---|---|---|---|
| 1 | AVEANNA HEALTHCARE HOLDINGS INC (AVAH) | Health Care | +115.7% | +9.2% | $2.8B |
| 2 | Cencora (COR) | Health Care | +103.1% | +0.5% | $65.5B |
| 3 | Medpace (MEDP) | Health Care | +98.3% | +17.8% | $17.4B |
| 4 | RIGEL PHARMACEUTICALS INC (RIGL) | Health Care | +93.8% | n/a | $899M |
| 5 | Amgen (AMGN) | Health Care | +89.1% | +21.0% | $237.3B |
| 6 | NRC HEALTH (NRC) | Health Care | +82.9% | +8.4% | $458M |
| 7 | Zoetis (ZTS) | Health Care | +80.2% | +28.2% | $33.1B |
| 8 | Lilly (Eli) (LLY) | Health Care | +77.8% | +31.7% | $1.21T |
| 9 | TG THERAPEUTICS INC (TGTX) | Health Care | +69.0% | +72.6% | $8.3B |
| 10 | Idexx Laboratories (IDXX) | Health Care | +66.0% | +24.6% | $44.0B |
| 11 | LIFEMD INC (LFMD) | Health Care | +62.0% | +7.4% | $108M |
| 12 | ZEVRA THERAPEUTICS INC (ZVRA) | Health Care | +53.8% | n/a | $622M |
| 13 | NOVO NORDISK A S (NVO) | Health Care | +52.8% | +33.1% | $174.9B |
| 14 | AURINIA PHARMACEUTICALS INC (AUPH) | Health Care | +49.4% | n/a | $2.2B |
| 15 | ABEONA THERAPEUTICS INC (ABEO) | Health Care | +44.7% | n/a | $263M |
| 16 | CONCENTRA GROUP HOLDINGS PARENT IN (CON) | Health Care | +41.5% | +7.7% | $4.9B |
| 17 | CORMEDIX INC (CRMD) | Health Care | +40.2% | +52.3% | $590M |
| 18 | TRANSMEDICS GROUP INC (TMDX) | Health Care | +40.2% | +31.4% | $2.6B |
| 19 | Alnylam Pharmaceuticals (ALNY) | Health Care | +39.8% | +8.4% | $30.9B |
| 20 | Tenet Healthcare (THC) | Health Care | +39.3% | +11.1% | $21.9B |
| 21 | Bristol Myers Squibb (BMY) | Health Care | +38.2% | +14.6% | $126.0B |
| 22 | Gilead Sciences (GILD) | Health Care | +37.6% | +28.9% | $194.1B |
| 23 | Exelixis (EXEL) | Health Care | +36.2% | +33.7% | $16.0B |
| 24 | THERAVANCE BIOPHARMA INC (TBPH) | Health Care | +35.7% | +98.5% | $884M |
| 25 | Merck & Co. (MRK) | Health Care | +34.7% | +28.1% | $365.9B |
Find more highest return-on-equity health care companies like these →
Data: SEC EDGAR (filings) + market data (fundamentals, delayed daily-close). Every figure is shown with its as-of date on the company page; a company with no data for this metric is excluded from the ranking, never estimated.
Last updated 2026-10-20 — rankings shift as the underlying data refreshes.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.